Masimo (NASDAQ:MASI) has received an average rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $101.00.
Several brokerages have issued reports on MASI. BidaskClub raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research note on Tuesday, March 6th. Barclays began coverage on shares of Masimo in a research note on Friday, March 9th. They set an “overweight” rating and a $97.00 target price on the stock. Finally, Piper Jaffray reaffirmed a “hold” rating and set a $91.00 target price on shares of Masimo in a research note on Thursday, March 1st.
In other news, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $90.00, for a total transaction of $180,000.00. Following the transaction, the director now owns 70,249 shares in the company, valued at approximately $6,322,410. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Yongsam Lee sold 10,000 shares of Masimo stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $92.95, for a total value of $929,500.00. Following the transaction, the executive vice president now owns 79,000 shares in the company, valued at approximately $7,343,050. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,403 shares of company stock worth $4,040,693. 16.60% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Masimo by 7.4% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 10,368 shares of the medical equipment provider’s stock worth $879,000 after acquiring an additional 718 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Masimo by 39.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,820 shares of the medical equipment provider’s stock worth $239,000 after acquiring an additional 802 shares during the period. Brown Capital Management LLC raised its holdings in shares of Masimo by 0.8% during the 4th quarter. Brown Capital Management LLC now owns 98,506 shares of the medical equipment provider’s stock worth $8,353,000 after acquiring an additional 819 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of Masimo by 2.8% during the 4th quarter. Eagle Asset Management Inc. now owns 33,704 shares of the medical equipment provider’s stock worth $2,858,000 after acquiring an additional 932 shares during the period. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Masimo by 6.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 17,275 shares of the medical equipment provider’s stock worth $1,495,000 after acquiring an additional 980 shares during the period. Institutional investors and hedge funds own 82.79% of the company’s stock.
Masimo stock opened at $83.88 on Friday. Masimo has a 1 year low of $80.69 and a 1 year high of $104.71. The firm has a market capitalization of $4,475.84, a P/E ratio of 34.24, a P/E/G ratio of 2.28 and a beta of 0.94.
Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The company had revenue of $225.20 million for the quarter, compared to analysts’ expectations of $201.54 million. During the same quarter in the previous year, the company posted $0.46 EPS. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. equities analysts expect that Masimo will post 2.81 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/masimo-masi-receives-consensus-rating-of-buy-from-analysts.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.